Urinary levels of leukotriene E4 in acute asthmatic children

Year 2012, Volume: 4 Issue: 2, 1 - 6, 26.05.2012

Mohammed Abdel Fattah , Nehal El Rifai Nadia Swelam

Abstract

Background and Aims: Increased production of cysteinyl leukotrienes (CysLTs) within the airways causes acute asthma. Leukotriene E4 (LTE4) is a potent constricting mediator and is excreted in urine. This study hypothesized that urinary LTE4 (uLTE4) levels would be increased in acute asthma in Egyptian children. The study measured uLTE4 in children with acute asthma and compared them to a matched healthy control group.

Material and Methods: The study included 40 acute Egyptian asthmatic children and 40 age-and sex-matched controls. All candidates were subjected to a complete clinical study (thorough history and physical examination); with emphasis on severity of asthma attack according to Global Initiative for Asthma Guidelines. Measurement of urinary creatinine was performed for all study candidates. Measurement of uLTE4 (pg/mg creatinine) was performed using commercial ELISA kit.

Results: Levels of uLTE4 were significantly higher in cases compared to controls (305.48 ± 34 pg/mg creatinine versus 175.55 ± 79 pg/mg creatinine respectively, 95% CI (17.7; 242.1), p=0.024).Levels of uLTE4 were significantly higher in cases with moderate and severe attacks in comparison to those with mild attacks. There was a significant positive correlation between severity of the attack and uLTE4 levels (Spearman's rho = 0.446, p=0.004).

Conclusion: Levels of uLTE4 are significantly elevated during acute asthma episodes in children. The significant direct correlation between severity of these attacks and uLTE4 levels make uLTE4 a possible marker for monitoring acute asthma exacerbations in children.

Keywords

Asthma, acute, uLTE4, children

References

• Szefler SJ. Advances in pediatric asthma in 2010: addressing the major issues. J Allergy Clin Immunol, 2011; 127(1):102-15.
• Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2009. Vital Health Stat 10, 2010; (247):1-82.
• Yavuz ST, Civelek E, Tuncer A, Sahiner UM, Sekerel BE. Predictive factors for airway hyperresponsiveness in children with respiratory symptoms. Ann Allergy Asthma Immunol, 2011; 106(5):365-70.
• Sala KA, Carroll CL, Tang YS, Aglio T, Dressler AM, Schramm development of severe asthma exacerbations in children. J Asthma, 2011; 48(6):558-64. with the
• Micheletto C, Visconti M, Trevisan F, Tognella S, Bertacco S, Dal Negro RW. The prevalence of nasal polyps and the corresponding urinary LTE4 levels in severe compared to mild and moderate asthma, Eur Ann Allergy Clin Immunol, 2010; 42(3):120-4.
• Oommen A, Grigg J. Urinary leukotriene E4 in preschool children with acute clinical viral wheeze. Eur Respir J, 2003; 21: 149-154.
• Rabinovitch N, Reisdorph N, Silveira L, Gelfand EW. Urinary leukotriene E (4) levels identify children with tobacco smoke exposure at risk for asthma exacerbation. J Allergy Clin Immunol, 2011; 128(2):323-7.
• Severien C, Artlich A, Jonas S, Becher G. Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma. Eur Respir J 2000; 16: 588-592.
• Green SA, Malice MP, Tanaka W, Tozzi CA, Reiss TF. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax, 2004; 59:100-104.
• Power and Sample Size Calculation. Department of Biostatistics, Vanderbilt University available online at: http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/P owerSampleSize. Accessed May 15, 2011.
• Global Initiative for Asthma (GINA) Guidelines update 2010, http://www.ginasthma.com/download.asp?intId=430. Accessed May 15, 2011. online at:
• World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Revised by the 59th WMA General Assembly. http://www.wma.net/en/30publications/10policies/b3/i ndex.html. Accessed May 15, 2011. online at:
• He MJ, Chen Q, Liu JM. Urinary leukotriene E (4) level in children with asthma. Zhongguo Dang Dai Er Ke Za Zhi, 2009; 11(11): 909-12.
• Bizzintino JA, Khoo SK, Zhang G, Martin AC, Rueter K, Geelhoed GC, et al. Leukotriene pathway polymorphisms are associated with altered cysteinyl leukotriene production in children with acute asthma. Prostaglandins Leukot Essent Fatty Acids, 2009; 81(1): 9-15.
• Nakagome K, Nagata M. Pathogenesis of airway inflammation in bronchial asthma. Auris Nasus Larynx, 2011; 38(5):555-63.
• Okunishi K, Peters-Golden M. Leukotrienes and airway inflammation. Biochim Biophys Acta, 2011; 1810(11):1096-102.
• Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional 85(6):336-49. Pharmacology, 2010; 18- Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy. 2010; 40(12):1732-41.
• Haeggström JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A. Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun, 2010; 396(1):135-9.
• Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol, 2009; 124(3):406-14.
• Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional 85(6):336-49. Pharmacology, 2010;